Characterization of structure and function of ZS-9, a K+ selective ion trap

PLoS ONE

Volumn 9, Issue 12, 2014, Pages

  Stavros, Fiona ^a   Yang, Alex ^b   Leon, Alejro ^a   Nuttall, Mark ^a   Rasmussen, Henrik S ^a  

^a ZS Pharma   (United States)

^b Xelay Acumen Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM ION; MAGNESIUM ION; POLYMER; RESIN; SODIUM ZIRCONIUM CYCLOSILICATE; CALCIUM; ION; POTASSIUM; SILICATE; SODIUM; ZS-9 COMPOUND;

ARTICLE; CHANNEL GATING; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG SPECIFICITY; DRUG STRUCTURE; HYPERKALEMIA; ION EXCHANGE; LIMIT OF DETECTION; PARTICLE SIZE; PH MEASUREMENT; POTASSIUM EXCHANGE CAPACITY; STOMACH JUICE; STRUCTURE ACTIVITY RELATION; BLOOD; CHEMISTRY; HUMAN; METABOLISM; PATHOLOGY; PH; POROSITY;

CALCIUM; HUMANS; HYDROGEN-ION CONCENTRATION; HYPERKALEMIA; ION EXCHANGE; IONS; POROSITY; POTASSIUM; SILICATES; SODIUM;

EID: 84919665299     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0114686     Document Type: Article

References (34)

1. Svensson M, Gustafsson F, Galatius S, Hildebrandt PR, Atar D (2004) How prevalent is hyperkalemia and renal dysfunction during treatment with spironolactone in patients with congestive heart failure? J Card Fail 10: 297-303.
2. Elliott MJ, Ronksley PE, Clase CM, Ahmed SB, Hemmelgarn BR (2010) Management of patients with acute hyperkalemia. CMAJ 182: 1631-1635.
3. Lehnhardt A, Kemper MJ (2011) Pathogenesis, diagnosis and management of hyperkalemia. Pediatr Nephrol 26: 377-384.
4. Stevens MS, Dunlay RW (2000) Hyperkalemia in hospitalized patients. Int Urol Nephrol 32: 177-180.
5. Navaneethan SD, Nigwekar SU, Sehgal AR, Strippoli GF (2009) Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol 4: 542-551.
6. Tamirisa KP, Aaronson KD, Koelling TM (2004) Spironolactone-induced renal insufficiency and hyperkalemia in patients with heart failure. Am Heart J 148: 971-978.
7. Gennari FJ (2002) Disorders of potassium homeostasis. Hypokalemia and hyperkalemia. Crit Care Clin 18: 273-288, vi.
8. Fang J, Madhavan S, Cohen H, Alderman MH (2000) Serum potassium and cardiovascular mortality. J Gen Intern Med 15: 885-890.
9. Kim HJ, Han SW (2002) Therapeutic approach to hyperkalemia. Nephron 92 Suppl 1:: 33-40.
10. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, et al. (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341: 709-717.
11. Matoba S, Tatsumi T, Keira N, Kawahara A, Akashi K, et al. (1999) Cardioprotective effect of angiotensin-converting enzyme inhibition against hypoxia/reoxygenation injury in cultured rat cardiac myocytes. Circulation 99: 817-822.
12. Derthoo D, Belmans A, Claes K, Bammens B, Ciarka A, et al. (2013) Survival and heart failure therapy in chronic dialysis patients with heart failure and reduced left ventricular ejection fraction: an observational retrospective study. Acta Cardiol 68: 51-57.
13. Watson M, Abbott KC, Yuan CM (2010) Damned if you do, damned if you don't: potassium binding resins in hyperkalemia. Clin J Am Soc Nephrol 5: 1723-1726.
14. Sodium Polystyrene Sulfonate (Kayexalate) [prescribing information]. Available: http://products. sanofi.us/kayexalate/kayexalate.pdf. Accessed 2014 May 27.
15. Sterns RH, Rojas M, Bernstein P, Chennupati S (2010) Ion-exchange resins for the treatment of hyperkalemia: are they safe and effective? J Am Soc Nephrol 21: 733-735.
16. Emmett M, Hootkins RE, Fine KD, Santa Ana CA, Porter JL, et al. (1995) Effect of three laxatives and a cation exchange resin on fecal sodium and potassium excretion. Gastroenterology 108: 752-760.
17. Schroeder HA, Balassa JJ (1966) Abnormal trace metals in man: zirconium. J Chronic Dis 19: 573-586.
18. Bem D, Sherman J, Napolitano A, Leon-Escamilla E, Lewis G, et al. (1999) Zirconium silicate molecular sieves and process using the same. US Patent 005888472A. Available: http://www.google. com/patents/US5888472. Accessed 2014 Feb 25.
19. Bem D, Sherman J, Napolitano A, Leon-Escamilla E, Lewis GJ, et al. (1999) Zirconium silicate and zirconium germanate molecular sieves and process using the same. US Patent 005891417A. Available: http:http://www.google.com/patents/US5891417. Accessed 2014 Feb 25.
20. Bem D, Sherman J, Ash SR, Marte J, Willis R, et al. (2001) Ammonium removal with a novel zirconium silicate. ASAIO J 47: 151.
21. Doyle DA, Morais Cabral J, Pfuetzner RA, Kuo A, Gulbis JM, et al. (1998) The structure of the potassium channel: molecular basis of K+ conduction and selectivity. Science 280: 69-77.
22. Fulton T. Diffusion and transport across cell membranes (lecture). Available: http://biochemistry.ucsf. edu/programs/ptf/prologue links/Diff & Trans Membranes.pdf. Accessed 2014 Apr 23.
23. National Kidney Foundation Kidney Disease Outcomes Quality Initiative (NKF KDOQI) (2002) Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease. Available: http://www.kidney.org/professionals/kdoqi/guidelines-bone/guide6.htm. Accessed 2014 Mar 8.
24. Kosiborod M, Rasmussen HS, Lavin P, Qunibi WY, Spinowitz B, et al. (2014) Effect of Sodium Zirconium Cyclosilicate on Potassium Lowering for 28 Days Among Outpatients With Hyperkalemia: The HARMONIZE Randomized Clinical Trial. JAMA: DOI 10.1001/jama.2014.15688.
25. Ash S, Singh B, Lavin P, Stavros F, Rasmussen H (2014) Safety and Efficacy of ZS-9, a Novel, Selective Potassium Trap: a Phase 2 Study of the Treatment of Hyperkalemia in Patients with Chronic Kidney Disease. Kidney Int: in press.
26. Packham D, Rasmussen H, Lavin P, El-Shahawy M, Roger S, et al. (2014) Sodium zirconium cyclosilicate in hyperkalemia. N Engl J Med: DOI 10.1056/NEJMoa1411487.
27. Bem D, Bedard R, Broach R, Leon-Escamilla E, Gisselquist J, et al. (1999) Synthesis and characterization of a new family of microporous zirconium silicates. Mat Res Soc Symp Proc 549: 73-78.
28. Yang A, Leon A, Nuttal M, Low J, Rasmussen H (2014) In vitro exchange capacity and selectivity of ZS-9, a novel, selective cation trap for the treatment of hyperkalemia. Am J Kidney Dis 63: A115.
29. Berlyne GM, Janabi K, Shaw AB, Hocken AG (1966) Treatment of hyperkalemia with a calcium-resin. Lancet 1: 169-172.
30. Marieb EN, Hoehn K (2010) Human anatomy and physiology. San Francisco: Benjamin Cummings.
31. Lee D, Roberts M, Bluchel C, Odell R (2010) Zirconium: Biomedical and nephrological applications. ASAIO J 56: 550-556.
32. Ash SR (2009) Sorbents in treatment of uremia: a short history and a great future. Semin Dial 22: 615-622.
33. Agar JW (2010) Review: understanding sorbent dialysis systems. Nephrology (Carlton) 15: 406-411.
34. Volkov A, Paula S, Deamer D (1997) Two mechanisms of permeation of small neutral molecules and hydrated ions across phospholipid bilayers. Bioelectrochem Bioenerg 42: 153-160.